Söndag 10 Maj | 08:29:42 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-08-31 07:00 Kvartalsrapport 2026-Q2
2026-05-11 N/A X-dag ordinarie utdelning CRNA 0.00 NOK
2026-05-08 - Årsstämma
2026-04-15 - Bokslutskommuniké 2025
2026-01-12 - Extra Bolagsstämma 2026
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2025-06-05 - Årsstämma
2025-04-10 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-05-06 14:34:00

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 6 May 2026 – Circio Holding ASA (OSE: CRNA) ("Circio" or the "Company"), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, provides practical information relating to the exercise of warrants issued as part of the financing transaction in February 2026.

A total of 67,680,945 warrants were issued on ISIN NO0013711523 in connection with the rights issue and related private placement (Nw.: frittstående tegningsretter) (the "Warrants"), as announced in the stock exchange announcement published on 16 February 2026.

Key terms and dates:

  • Warrants outstanding: 67,680,945
  • Warrant exercise terms: Each Warrant gives the holder the right to subscribe for one (1) new share in Circio at the exercise price
  • Warrant trading: The Warrants are listed and tradable on the Oslo Stock Exchange under the ticker code "CRNAS" with ISIN NO0013711523
  • Warrant trading period: The Warrants are tradable to and including 3 June 2026
  • Warrant pricing period: 8-22 May 2026
  • Warrant exercise price: 20% discount to the volume-weighted average trading price (VWAP) of the shares of Circio during the Warrant pricing period (cf. above)
  • Announcement of exercise price: After market close on 22 May 2026 (Newsweb)
  • Warrant exercise period: 26 May - 9 June 2026
  • Unexercised Warrants: Warrants not exercised by the end of the exercise period will lapse without any compensation to the holder
  • Warrant payment date: On or about 12 June 2026
  • Tradability and delivery of new shares: As soon as practicable after the Warrant payment date

Main alternatives for Warrant holders:

  1. Exercise currently held Warrants during the exercise period, pay the exercise price and receive new shares in Circio.
  2. Buy additional Warrants on the Oslo Stock Exchange. Subsequently exercise all held Warrants during the exercise period, pay the exercise price and receive new shares in Circio.
  3. Sell a portion of currently held Warrants during the trading period. Subsequently exercise the remaining Warrants held during the exercise period, pay the exercise price and receive shares in Circio.
  4. Sell all currently held Warrants during the trading period on the Oslo Stock Exchange.
  5. Do nothing. Warrants not exercised by 9 June 2026 will lapse without any compensation to the holder.


Information related to financing of Warrants:
With regard to the first 3 alternatives above (involving the exercise of Warrants), exercising Warrants means buying new shares in Circio at the exercise price (20% discount to VWAP as mentioned above), and the aggregate exercise price must be settled with cash on the Warrant payment date (on or about 12 June 2026).

It is imperative that investors planning to exercise Warrants secure sufficient financing to cover the aggregate exercise price ahead of the Warrant payment date.

Illustrative example: A holder of 100,000 Warrants (representing the right to buy 100,000 new shares in Circio at the exercise price) would need to pay the exercise price multiplied by the number of Warrants to exercise all Warrants. For example, at an exercise price of NOK 5, NOK 7.5 or NOK 10 per share, the holder would need NOK 500,000, NOK 750,000 or NOK 1,000,000, respectively, to exercise all Warrants.

How to exercise Warrants:
During the exercise period, Warrants can be exercised (i) digitally through the websites of Pareto Securities and Circio, or (ii) manually by contacting Pareto Securities directly. More information about this will be announced after the exercise price has been set on 22 May 2026, ahead of the exercise period commencing on 26 May 2026.

Further information about the Warrants:
The grant or purchase of Warrants by persons resident in, or who are citizens of countries other than Norway or Sweden, may be affected by the laws of the relevant jurisdiction. For a further description of such restrictions, reference is made to Section 11 "Selling and Transfer Restrictions" in the securities note dated 13 January 2026 (the "Securities Note", and together with a registration document dated 1 October 2025, and a registration document supplement and summary dated 13 January 2026, comprise the "Prospectus").

For more information about the Warrants, please refer to the Prospectus. The Prospectus is available on the Company's website: https://www.circio.com/en/rightsissue2026/.